Am J Perinatol
DOI: 10.1055/s-0044-1779255
Original Article

Phenobarbital as a Sedation Strategy to Reduce Opioid and Benzodiazepine Burden in Neonatal Extracorporeal Membrane Oxygenation

1   Division of Neonatology, Department of Pediatrics, St. Christopher's Hospital for Children, Philadelphia, Pennsylvania
2   Department of Pediatrics, Drexel University College of Medicine, Philadelphia, Pennsylvania
,
2   Department of Pediatrics, Drexel University College of Medicine, Philadelphia, Pennsylvania
,
Michelle Mejia
1   Division of Neonatology, Department of Pediatrics, St. Christopher's Hospital for Children, Philadelphia, Pennsylvania
,
Swosti Joshi
1   Division of Neonatology, Department of Pediatrics, St. Christopher's Hospital for Children, Philadelphia, Pennsylvania
2   Department of Pediatrics, Drexel University College of Medicine, Philadelphia, Pennsylvania
,
Ogechukwu Menkiti
1   Division of Neonatology, Department of Pediatrics, St. Christopher's Hospital for Children, Philadelphia, Pennsylvania
2   Department of Pediatrics, Drexel University College of Medicine, Philadelphia, Pennsylvania
› Author Affiliations
Funding None.

Abstract

Objective The study aims to describe our experience with the implementation of phenobarbital as a primary sedation strategy during neonatal extracorporeal membrane oxygenation (ECMO).

Study Design Retrospective chart review in a level IV neonatal intensive care unit between 2011 and 2021 comparing neonatal ECMO patients before and after the implementation of a sedation-analgesia (SA) protocol using scheduled phenobarbital as the primary sedative. Groups were compared for neonatal and ECMO characteristics, cumulative SA doses, and in-hospital outcomes. Comparison between groups was performed using Mann–Whitney test on continuous variables and chi-square on nominal variables.

Results Forty-two patients were included, 23 preprotocol and 19 postprotocol. Birth, pre-ECMO, and ECMO clinical characteristics were similar between groups except for a lower birth weight in the postprotocol group (p = 0.024). After standardization of phenobarbital SA protocol, there was a statistically significant reduction in median total morphine dose (31.38–17.65 mg/kg, p = 0.006) and median total midazolam dose (36.21–6.36 mg/kg, p < 0.001). There was also a reduction in median total days on morphine by 7.5 days (p = 0.026) and midazolam by 6.6 days (p = 0.003). There were no differences in ECMO duration or in-hospital outcomes between groups.

Conclusion In this cohort, short-term use of phenobarbital as primary sedation strategy during neonatal ECMO was associated with reduced opioid and midazolam burden. Such reduction, however, did not affect in-hospital outcomes.

Key Points

  • Prolonged sedation on ECMO puts infants at risk for iatrogenic withdrawal.

  • Phenobarbital is a feasible sedation strategy for ECMO.

  • Phenobarbital sedation strategy may mitigate risk by decreasing opioid and midazolam burden.

Availability of Data and Materials

The data were extracted from patient charts and database can be provided upon request.


Authors' Contribution

Construction of the project was created by V.Q.C., S.J., and O.M. Data collection was conducted by E.B. and M.M. Statistical analysis was done by V.Q.C. and S.J. First draft of manuscript was written by E.B. and V.Q.C. All authors edited and approved manuscript.


Supplementary Material



Publication History

Received: 06 August 2023

Accepted: 01 January 2024

Article published online:
16 February 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Fletcher K, Chapman R, Keene S. An overview of medical ECMO for neonates. Semin Perinatol 2018; Mar; 42 (02) 68-79
  • 2 Franciscovich CD, Monk HM, Brodecki D. et al. Sedation practices of neonates receiving extracorporeal membrane oxygenation. ASAIO J 2020; 66 (05) 559-564
  • 3 Dominguez KD, Lomako DM, Katz RW, Kelly HW. Opioid withdrawal in critically ill neonates. Ann Pharmacother 2003; 37 (04) 473-477
  • 4 Franck LS, Vilardi J, Durand D, Powers R. Opioid withdrawal in neonates after continuous infusions of morphine or fentanyl during extracorporeal membrane oxygenation. Am J Crit Care 1998; 7 (05) 364-369
  • 5 Arnold JH, Truog RD, Orav EJ, Scavone JM, Hershenson MB. Tolerance and dependence in neonates sedated with fentanyl during extracorporeal membrane oxygenation. Anesthesiology 1990; 73 (06) 1136-1140
  • 6 Liu G, Kong L, Leslie DL, Corr TE. A longitudinal healthcare use profile of children with a history of neonatal abstinence syndrome. J Pediatr 2019; 204: 111-117.e1
  • 7 Oei JL. After NAS. Semin Fetal Neonatal Med 2019; 24 (02) 161-165
  • 8 Zwicker JG, Miller SP, Grunau RE. et al. Smaller cerebellar growth and poorer neurodevelopmental outcomes in very preterm infants exposed to neonatal morphine. J Pediatr 2016; 172: 81-87.e2
  • 9 Beltrán-Campos V, Silva-Vera M, García-Campos ML, Díaz-Cintra S. Effects of morphine on brain plasticity. Neurología 2015; 30 (03) 176-180 (English edition)
  • 10 de Graaf J, van Lingen RA, Simons SHP. et al. Long-term effects of routine morphine infusion in mechanically ventilated neonates on children's functioning: five-year follow-up of a randomized controlled trial. Pain 2011; 152 (06) 1391-1397
  • 11 Pacifici GM. Clinical pharmacology of phenobarbital in neonates: effects, metabolism and pharmacokinetics. Curr Pediatr Rev 2016; 12 (01) 48-54
  • 12 Anand KJS, Hall RW. Pharmacological therapy for analgesia and sedation in the newborn. Arch Dis Child Fetal Neonatal Ed 2006; 91 (06) F448-F453
  • 13 Kocherlakota P. Neonatal abstinence syndrome. Pediatrics 2014; 134 (02) e547-e561
  • 14 Kwan P, Brodie MJ. Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia 2004; 45 (09) 1141-1149
  • 15 Pöschl J, Kölker S, Bast T. et al. Gamma-hydroxybutyric acid sedation in neonates and children undergoing MR imaging. Klin Padiatr 2007; 219 (04) 217-219
  • 16 Elliott ESR, Buck ML. Phenobarbital dosing and pharmacokinetics in a neonate receiving extracorporeal membrane oxygenation. Ann Pharmacother 1999; 33 (04) 419-422
  • 17 Wild KT, Rintoul N, Kattan J, Gray B. Extracorporeal Life Support Organization (ELSO): guidelines for neonatal respiratory failure. ASAIO J 2020; 66 (05) 463-470
  • 18 Scott BL, Bonadonna D, Ozment CP, Rehder KJ. Extracorporeal membrane oxygenation in critically ill neonatal and pediatric patients with acute respiratory failure: a guide for the clinician. Expert Rev Respir Med 2021; 15 (10) 1281-1291
  • 19 Wildschut ED, Hanekamp MN, Vet NJ. et al. Feasibility of sedation and analgesia interruption following cannulation in neonates on extracorporeal membrane oxygenation. Intensive Care Med 2010; 36 (09) 1587-1591
  • 20 Smith HAB, Besunder JB, Betters KA. et al. 2022 Society of Critical Care Medicine Clinical Practice Guidelines on Prevention and Management of Pain, Agitation, Neuromuscular Blockade, and Delirium in Critically Ill Pediatric Patients With Consideration of the ICU Environment and Early Mobility. Pediatr Crit Care Med 2022; 23 (02) e74-e110
  • 21 Schloss B, Hayes Jr D, Tobias JD. Phenobarbital use in an infant requiring extracorporeal membrane life support. J Anaesthesiol Clin Pharmacol 2013; 29 (01) 92-94
  • 22 Zimmerman KO, Dallefeld SH, Hornik CP, Watt KM. Sedative and analgesic pharmacokinetics during pediatric ECMO. J Pediatr Pharmacol Ther 2020; 25 (08) 675-688
  • 23 Michaličková D, Pokorná P, Tibboel D, Slanař O, Knibbe CAJ, Krekels EHJ. Rapid increase in clearance of phenobarbital in neonates on extracorporeal membrane oxygenation: a pilot retrospective population pharmacokinetic analysis. Pediatr Crit Care Med 2020; 21 (09) e707-e715
  • 24 Pokorná P, Šíma M, Vobruba V, Tibboel D, Slanař O. Phenobarbital pharmacokinetics in neonates and infants during extracorporeal membrane oxygenation. Perfusion 2018; 33 (1_suppl): 80-86
  • 25 Puia-Dumitrescu M, Comstock BA, Li S. et al; PENUT Consortium. Assessment of 2-year neurodevelopmental outcomes in extremely preterm infants receiving opioids and benzodiazepines. JAMA Netw Open 2021; 4 (07) e2115998-e2115998
  • 26 Maitre NL, Smolinsky C, Slaughter JC, Stark AR. Adverse neurodevelopmental outcomes after exposure to phenobarbital and levetiracetam for the treatment of neonatal seizures. J Perinatol 2013; 33 (11) 841-846
  • 27 Qiao M-Y, Cui H-T, Zhao L-Z, Miao J-K, Chen Q-X. Efficacy and safety of levetiracetam vs. phenobarbital for neonatal seizures: a systematic review and meta-analysis. Front Neurol 2021; 12: 747745
  • 28 Sharpe C, Reiner GE, Davis SL. et al; NEOLEV2 INVESTIGATORS. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial. Pediatrics 2020; 145 (06) e20193182
  • 29 Keene JC, Morgan LA, Abend NS. et al. Treatment of neonatal seizures: comparison of treatment pathways from 11 neonatal intensive care units. Pediatr Neurol 2022; 128: 67-74
  • 30 Boyle K, Felling R, Yiu A. et al. Neurologic outcomes after extracorporeal membrane oxygenation: a systematic review. Pediatr Crit Care Med 2018; 19 (08) 760-766
  • 31 Dhar AV, Scott S, Anton-Martin P. et al. Neurodevelopmental outcomes in extracorporeal membrane oxygenation patients: a pilot study. ASAIO J 2020; 66 (04) 447-453
  • 32 Natarajan G, Hamrick SE, Zaniletti I. et al; Children's Hospitals Neonatal Database Hypoxic-Ischemic Encephalopathy Focus group. Opioid exposure during therapeutic hypothermia and short-term outcomes in neonatal encephalopathy. J Perinatol 2022; 42 (08) 1017-1025